MedTrace Logo

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

NCT04708834 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 772

Last updated 2026-02-25

No results posted yet for this study

Summary

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).

Conditions

  • Obsessive Compulsive Disorder

Interventions

DRUG

Troriluzole (BHV-4157)

200 mg daily first 2 weeks, 280 daily following first 2 weeks

Sponsors & Collaborators

  • Biohaven Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2026-02-13
Completion
2026-02-13
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708834 on ClinicalTrials.gov